Patents by Inventor Pascal Furet

Pascal Furet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080262021
    Abstract: The invention relates to imidazoquinolines of formula (I) for use in the treatment of protein kinase dependent diseases; pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease; novel imidazoquinolines; and a process for the preparation of the novel imidazoquinolines.
    Type: Application
    Filed: November 19, 2004
    Publication date: October 23, 2008
    Applicant: NOVARTIS AG
    Inventors: Hans-Georg Capraro, Giorgio Caravatti, Pascal Furet, Carlos Garcia-Echeverria, Patricia Imbach, Frederic Stauffer
  • Publication number: 20080234284
    Abstract: The invention relates to pyrazolo[1,5a]pyrimidin-7-yl amine derivatives of formula (I) and salts thereof, their use in the treatment of protein kinase dependent diseases.
    Type: Application
    Filed: July 19, 2006
    Publication date: September 25, 2008
    Inventors: Patricia Imbach, Pascal Furet, Georg Martiny-Baron
  • Publication number: 20080214548
    Abstract: The invention relates to compounds of the formula I and salts thereof, to a process for their manufacture, to their use in the treatment of (especially cysteine protease, such as UCH-L3- and/or USP-2 dependent) diseases or for the manufacture of pharmaceutical formulations against these diseases, methods of treatment of warm-blooded animals comprising administering the compounds and/or their salts to said animals and pharmaceutical preparations, especially for the treatment of the diseases, comprising said compounds and/or salts.
    Type: Application
    Filed: July 17, 2006
    Publication date: September 4, 2008
    Inventors: Stefanie Flohr, Pascal Furet, Patricia Imabach, Ulrich Hommel, Hans-Ulrich litscher, Shirley Gil Parrado, Ulrich Hassiepen, Johann Zimmermann
  • Publication number: 20080194579
    Abstract: The invention relates to novel organic compounds of formula (I) processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment of an inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in connection with transplantation, or a proliferative disease, such as a tumor disease.
    Type: Application
    Filed: May 18, 2006
    Publication date: August 14, 2008
    Inventors: Carlos Garcia-Echeverria, Frederic Stauffer, Pascal Furet
  • Publication number: 20080188451
    Abstract: The invention relates to compounds of formula wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.
    Type: Application
    Filed: April 2, 2008
    Publication date: August 7, 2008
    Inventors: Werner Breitenstein, Pascal Furet, Sandra Jacob, Paul William Manley
  • Publication number: 20080167308
    Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
    Type: Application
    Filed: October 31, 2007
    Publication date: July 10, 2008
    Applicants: IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY, NOVARTIS, AG
    Inventors: Valentina Molteni, Xiaolin Li, Donatella Chianelli, Juliet Nabakka, Jon Loren, Xiaodong Liu, Shifeng Pan, Yi Liu, Donald S. Karanewsky, Pascal Furet, Vito Guagnano, Shuli You
  • Publication number: 20080139559
    Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
    Type: Application
    Filed: October 31, 2007
    Publication date: June 12, 2008
    Applicants: IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY, NOVARTIS
    Inventors: Valentina Molteni, Shuli You, Juliet Nabakka, Yi Liu, Xiaolin Li, Donatella Chianelli, Jon Loren, Xiaodong Liu, Shifeng Pan, Donald S. Karanewsky, Pascal Furet, Vito Guagnano
  • Publication number: 20080139597
    Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
    Type: Application
    Filed: October 31, 2007
    Publication date: June 12, 2008
    Applicants: IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY, NOVARTIS, AG
    Inventors: Valentina Molteni, Xiaolin Li, Donatella Chianelli, Jon Loren, Juliet Nabakka, Xiaodong Liu, Shifeng Pan, Yi Liu, Donald S. Karanewsky, Pascal Furet, Vito Guagnano, Shuli You
  • Publication number: 20080096868
    Abstract: The invention relates to 1,4-substituted pyrazolopyrimidine compounds of the formula I, pharmaceuticals comprising a 1,4-substituted pyrazolopyrimidine compound, the use of a 1,4-substituted pyrazolopyrimidine compound in the treatment or the use thereof in the manufacture of a pharmaceutical formulation for the treatment of a disease that depends on inadequate activity of a protein kinase, methods of treatment comprising administering a 1,4-substituted pyrazolopyrimidine compound, methods for the manufacture of a novel compound of that class, and novel intermediates and partial steps for their synthesis.
    Type: Application
    Filed: November 10, 2005
    Publication date: April 24, 2008
    Inventors: Niko Schmiedeberg, Pascal Furet, Patricia Imbach, Philipp Holzer
  • Publication number: 20080096883
    Abstract: The invention relates to trifluoromethyl substituted benzamide compounds of the formula (I), pharmaceuticals comprising these compounds, their use as or for the manufacture of pharmaceuticals, particularly as inhibitors of protein kinases and/or the treatment of a condition, disorder or disease state mediated by a protein kinase activity and/or a proliferative disease, methods of treatment comprising administering the compounds, especially of therapeutic and prophylactic treatment, methods for the manufacture of the compounds and novel intermediates and partial steps for their synthesis.
    Type: Application
    Filed: August 10, 2005
    Publication date: April 24, 2008
    Inventors: Giorgio Caravatti, Pascal Furet, Patricia Imbach, Georg Martiny-Baron, Lawrence Blas Perez, Tao Sheng
  • Publication number: 20080039440
    Abstract: The invention relates to novel compounds of Formula I: wherein p is 1, 2 or 3; n is 0, 1, 2 or 3; m is 0, 1, 2 or 3; A is CRc, S, NRc or O, where Rc is H or lower alkyl; X, Y and Z are each independently selected from N or C—R3, wherein at least two of X, Y and Z are N; and each Ra is independently selected from hydrogen and lower-alkyl; each Rb is hydrogen or lower-alkyl; G is a group Ar or represents CN or unsubstituted or substituted lower alkyl; Ar is a saturated or unsaturated cyclic group, which is substituted or unsubstituted and maybe a five or six membered monocyclic or a 8, 9, 10, 11 or 12 membered bicyclic or tricyclic ring and may contain 0, 1, 2 or 3 heteroatoms selected from O, N and S; and wherein the radicals have R1, R2, R3 and R4 have the meanings as defined herein, to salts, esters, N-oxides or prodrugs thereof; and their use in the treatment of protein kinase dependent diseases, their use in the manufacture of pharmaceutical compositions for use in the treatment of said diseases
    Type: Application
    Filed: September 27, 2005
    Publication date: February 14, 2008
    Inventors: Guido Bold, Giorgio Caravatti, Andreas Floersheimer, Pascal Furet, Paul Manley, Carole Pissot Soldermann, Andrea Vaupel
  • Patent number: 7326699
    Abstract: The invention relates to new 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof-alone or in combination with one or more other pharmaceutically active compounds-for the treatment of a disease, especially a proliferative disease, such as a tumour disease, a method for the treatment of such diseases in mammals, especially in humans, and the use of such a compound-alone or in combination with one or more other pharmaceutically active compounds-for the preparation of a pharmaceutical composition (medicament) for the treatment especially of a proliferative disease, such as a tumour.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: February 5, 2008
    Assignee: Novartis AG
    Inventors: Hans-Georg Capraro, Pascal Furet, Carlos Garcia-Echeverria, Paul William Manley
  • Publication number: 20070249639
    Abstract: The invention relates to the use of 9H-purine-2,6-diamine compounds and salts thereof in the treatment of proliferative diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, pharmaceutical preparations comprising 9H-purine-2,6-diamine compounds, novel 9H-purine-2,6-diamine compounds, and a process for the preparation of the novel 9H-purine-2,6-diamine compounds.
    Type: Application
    Filed: April 4, 2005
    Publication date: October 25, 2007
    Inventors: Rolf Baenteli, Patrick Chene, Stephen Collingwood, Pascal Furet, Peter Meier, Joseph Schoepfer
  • Publication number: 20070213355
    Abstract: The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.
    Type: Application
    Filed: November 19, 2004
    Publication date: September 13, 2007
    Inventors: Hans-Georg Capraro, Pascal Furet, Carlos Garcia-Cheverria, Frederic Stauffer
  • Publication number: 20070167449
    Abstract: The invention relates to thiazole and pyrazole derivatives of formula (I) wherein Q is S and X is C, or Q is CH and X is N; R1 is unsubstituted or substituted phenyl; and R2 is unsubstituted or substituted aryl or heteroaryl; or a salt of the said compounds, and to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumour disease, in particular such diseases which respond to an inhibition of the Flt-3 kinase.
    Type: Application
    Filed: November 12, 2004
    Publication date: July 19, 2007
    Inventors: Guido Bold, Andreas Floersheimer, Pascal Furet, Vito Guagnano, Keiichi Masuya, Andrea Vaupel, Joseph Schoepfer
  • Publication number: 20070149538
    Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
    Type: Application
    Filed: September 26, 2006
    Publication date: June 28, 2007
    Applicants: IRM LLC, Novartis, AG
    Inventors: Valentina Molteni, Xiaolin Li, Donatella Chianelli, Jon Loren, Shuli You, Juliet Nabakka, Xiadong Liu, Shifeng Pan, Yi Liu, Donald Karanewsky, Pascal Furet, Vito Guagnano
  • Publication number: 20070093506
    Abstract: The invention relates to compounds of formula wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.
    Type: Application
    Filed: December 1, 2006
    Publication date: April 26, 2007
    Inventors: Werner Breitenstein, Pascal Furet, Sandra Jacob, Paul Manley
  • Patent number: 7189729
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, EGF-R, c-erbB2 kinase (HER-2), CHK2, FGFR3, p70S6K, PKC, PDGF-R, p38, TGF?, KDR, c-Kit, b-RAF, c-RAF, FLT1 and/or FLT4 kinases.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: March 13, 2007
    Assignee: IRM LLC
    Inventors: Greg Chopiuk, Pascal Furet, Nathanael Schiander Gray, Patricia Imbach, Yi Liu, Joseph Schoepfer, Ruo Steensma
  • Patent number: 7169791
    Abstract: The invention relates to compounds of formula wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.
    Type: Grant
    Filed: July 4, 2003
    Date of Patent: January 30, 2007
    Assignee: Novartis AG
    Inventors: Werner Breitenstein, Pascal Furet, Sandra Jacob, Paul William Manley
  • Patent number: 7122547
    Abstract: The invention relates to anthranilic acid amides and the use thereof as medicaments for the treatment of diseases that are triggered by persistent angiogenesis, in addition to intermediate products in the production of anthranilic acid amides.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: October 17, 2006
    Assignees: Schering AG, Novartis AG
    Inventors: Andreas Huth, Dieter Seidelmann, Karl-Heinz Thierauch, Guido Bold, Paul William Manley, Pascal Furet, Jeanette Marjorie Wood, Jürgen Mestan, Jose Brüggen, Stefano Ferrari, Martin Krüger, Eckhard Ottow, Andreas Menrad, Michael Schirner